In the validation cohort, no differences were found between adiponectin and fibrosis stage and ballooning and lobular inflammation, neither for the presence/absence of co-morbidities nor for the other NAFLD risk-associated polymorphisms (Supplementary Figure 2). The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.